Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib
In recent years, there has been increasing pressure on public health systems in high-income countries due to high medicines prices, one of the underlying causes of which are the market monopolies granted to pharmaceutical undertakings. These monopolies have been facilitated by expanded forms of inte...
Main Authors: | Yuanqiong Hu, Dimitri Eynikel, Pascale Boulet, Gaelle Krikorian |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-12-01
|
Series: | Journal of Pharmaceutical Policy and Practice |
Subjects: | |
Online Access: | http://dx.doi.org/10.1186/s40545-019-0198-6 |
Similar Items
-
Inhibition of signal peptidase complex expression affects the development and survival of Schistosoma japonicum
by: Wen-Bin Yang, et al.
Published: (2023-03-01) -
Supplementary protection of intellectual property rights for medicines
by: A.O. Kodynets, et al.
Published: (2023-09-01) -
Comparison of the commodity certification systems in the European Union and in the Eurasian Economic Union
by: Valerii Kardanov, et al.
Published: (2019-03-01) -
ISO 22000 Certification: Diffusion in Europe
by: Nathalia Granja, et al.
Published: (2021-09-01) -
Halal Slaughterhouse Certification: The Comparison between Two Halal Certification Bodies
by: Sherly Artadita, et al.
Published: (2019-11-01)